GH Research (NASDAQ:GHRS) Shares Down 4.6% – What’s Next?

Shares of GH Research PLC (NASDAQ:GHRS) traded down 4.6% on Tuesday . The company traded as low as $12.92 and last traded at $13.07. 65,298 shares traded hands during trading, a decline of 65% from the average session volume of 184,651 shares. The stock had previously closed at $13.70.

Analyst Upgrades and Downgrades

Several research firms have weighed in on GHRS. Cantor Fitzgerald started coverage on shares of GH Research in a report on Wednesday, June 4th. They set an “overweight” rating and a $25.00 price objective on the stock. Guggenheim lowered their target price on shares of GH Research from $32.00 to $29.00 and set a “buy” rating on the stock in a report on Friday, May 9th. Royal Bank of Canada began coverage on GH Research in a research note on Friday, March 7th. They set an “outperform” rating and a $31.00 price target for the company. Wall Street Zen lowered GH Research from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. Finally, Stifel Nicolaus raised their target price on GH Research from $18.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, February 27th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

GH Research Trading Down 6.6%

The firm has a market cap of $665.91 million, a P/E ratio of -16.25 and a beta of 0.97. The business’s fifty day simple moving average is $10.45 and its 200-day simple moving average is $10.29.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.42. As a group, research analysts expect that GH Research PLC will post -0.8 earnings per share for the current fiscal year.

Institutional Trading of GH Research

Large investors have recently modified their holdings of the business. BNP Paribas Financial Markets purchased a new stake in GH Research in the fourth quarter valued at approximately $44,000. Northern Trust Corp lifted its holdings in shares of GH Research by 26.8% during the 4th quarter. Northern Trust Corp now owns 40,834 shares of the company’s stock worth $286,000 after acquiring an additional 8,641 shares during the last quarter. Woodline Partners LP grew its position in GH Research by 112.0% in the fourth quarter. Woodline Partners LP now owns 78,949 shares of the company’s stock worth $553,000 after acquiring an additional 41,711 shares in the last quarter. Lynx1 Capital Management LP increased its stake in GH Research by 15.8% in the fourth quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company’s stock valued at $34,013,000 after acquiring an additional 663,100 shares during the last quarter. Finally, Diadema Partners LP purchased a new stake in GH Research during the fourth quarter valued at about $711,000. Institutional investors own 56.90% of the company’s stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).